Determination of tenoxicam in human plasma by high-performance liquid chromatography

Heizmann, P.; Körner, J.; Zinapold, K.

doi:10.1016/s0378-4347(00)83256-9

Cited by 45 publications

(10 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Concentrations of tenoxicam in plasma were assayed by highperfonnance liquid chromatography (HPLC) (14). The detection limit of the assay was 25 nglml and the precision was 5%.…”

Section: Tenoxicam Assaymentioning

confidence: 99%

Plasma tenoxicam concentrations after single and multiple oral doses

Crevoisier

Heizmann

Forgo³

et al. 1989

Eur. J. Drug Metab. Pharmacokinet.

Self Cite

View full text Add to dashboard Cite

The pharmacokinetics of single- and multiple-dose administration of tenoxicam 20 mg were evaluated in 8 healthy males. Maximum plasma concentration (Cmax) after the first dose was 2.76 +/- 0.48 micrograms/ml (mean +/- s.d.) and the time to reach Cmax (Tmax) was 5.0 +/- 3.0 h. The area under the plasma concentration-time curve (AUC0-infinity) after a single administration of tenoxicam was 242.5 +/- 73.5 micrograms x h/ml. The elimination half-life (t1/2) was 66.3 +/- 15.8 h and the plasma concentration at 24 hours after dosing (Cmin) was 1.84 +/- 0.33 micrograms/ml. Steady-state plasma concentrations of tenoxicam were virtually reached after 10 consecutive daily doses. At steady-state, Cmax averaged 13.63 +/- 3.33 micrograms/ml and Tmax remained 5.0 +/- 3.0 hours. AUC within a dosing interval at steady-state was 262.2 +/- 67.0 micrograms x h/ml, Cminss was 9.67 +/- 3.25 micrograms/ml, and t1/2 averaged 74.2 +/- 13.3 h. The average fluctuation during multiple-dose administration was 26.8 +/- 8.0% and the accumulation ratio was 5.82 +/- 0.60. Steady-state pharmacokinetic parameters predicted from the first-dose data slightly underestimated observed values, but the results supported the assumption of linear pharmacokinetics during multiple-dose tenoxicam administration.

show abstract

“…Concentrations of tenoxicam in plasma were assayed by highperfonnance liquid chromatography (HPLC) (14). The detection limit of the assay was 25 nglml and the precision was 5%.…”

Section: Tenoxicam Assaymentioning

confidence: 99%

Plasma tenoxicam concentrations after single and multiple oral doses

Crevoisier

Heizmann

Forgo³

et al. 1989

Eur. J. Drug Metab. Pharmacokinet.

Self Cite

View full text Add to dashboard Cite

show abstract

“…Studies on its determination in human plasma by HPLC have been described [6][7][8]. With respect to its separation, identification and determination, a full study on human urine samples of patients and volunteers after oral administration of Tenoxicam, was carried out by Dell et al [9], using HPLC.…”

Section: Introductionmentioning

confidence: 99%

Polarographic behaviour of Aceclofenac, Tenoxicam and Droxicam in a methanol–water mixture

Acuña

Vázquez

Tascón

et al. 2004

Journal of Pharmaceutical and Biomedical Analysis

View full text Add to dashboard Cite

“…Both substances were determined in plasma according to the validated HPLCmethod of Heizmann et al (1986), with minor modifications. Both substances were determined in plasma according to the validated HPLCmethod of Heizmann et al (1986), with minor modifications.…”

Section: Methodsmentioning

confidence: 99%

Single- and Multiple-Dose Pharmacokinetics, Kidney Tolerability and Plasma Protein Binding of Tenoxicam in Renally Impaired Patients and Healthy Volunteers

et al. 2001

View full text Add to dashboard Cite

The 20 mg single-dose and 12 days repeated-dose pharmacokinetics of tenoxicam and the 5-OH-tenoxicam metabolite have been evaluated in healthy volunteers and two groups of patients with different degree of renal impairment, in total 20 persons. Concomitantly, the plasma protein binding of tenoxicam and the effects of treatment on renal function were evaluated. No differences were found between the investigated groups in the pharmacokinetics of total tenoxicam and the 5-OH metabolite did not interfere either with the pharmacokinetics or with the plasma protein binding of tenoxicam. A positive correlation was found between an increase in the free fraction (% F) of tenoxicam in plasma and a decrease in the plasma elimination half-life in the low creatinine clearance group (40-20 ml/min.) both after the single-dose and at steady-state. At steady-state, a non-linear correlation was demonstrated between a decrease in the urinary excretion of the 5-OH metabolite and a decrease in creatinine clearance from 130 to 20 ml/min. An increase in the plasma level of the 5-OH metabolite by three times was found in the low creatinine clearance group as compared to healthy subjects. 14C-Impurities of tenoxicam, as low as 1.2%, were shown to greatly influence the determination of the plasma protein binding (equilibrium dialysis) of the highly protein-bound tenoxicam due to a non-binding ability of the impurities to plasma proteins. No significant changes in renal parameters were found during the study. It can be concluded that the pharmacokinetics and plasma protein binding of tenoxicam and the pharmacokinetics of the 5-OH-tenoxicam metabolite are increasingly changed in subjects with a creatinine clearance below 40 ml/min. A decreased binding of tenoxicam to plasma proteins in low clearance patients is probably the reason for a faster elimination of tenoxicam in this group rather than a higher intrinsic hepatic metabolic activity. This study conducted in a low number of patients did not bring forward any new data indicating any adverse effects of tenoxicam on renal function.

show abstract

Determination of tenoxicam in human plasma by high-performance liquid chromatography

Cited by 45 publications

References 4 publications

Plasma tenoxicam concentrations after single and multiple oral doses

Plasma tenoxicam concentrations after single and multiple oral doses

Polarographic behaviour of Aceclofenac, Tenoxicam and Droxicam in a methanol–water mixture

Single- and Multiple-Dose Pharmacokinetics, Kidney Tolerability and Plasma Protein Binding of Tenoxicam in Renally Impaired Patients and Healthy Volunteers

Contact Info

Product

Resources

About